Good for us call. joining Thank QX morning, Rafael. Thanks, for everyone. you our
we year. you delivered strong press very another growth release, quarter in We our to financial performance excellent the a of start had line. on bottom top the As outstanding saw with and both
in including significant We As production. role across vaccine a we growth response a had markets, leadership of in accelerated quarter. already the society's starting business, businesses launching our accelerated base innovative you In in strong to investments initiated we're know, first new our growth growth strategy, to products, benefits a pandemic, strengthening expanding and high the execution of emerging proposition. very enabling value And playing our meaningfully customer we role number XXXX. the in our rapidly the unique including our all supporting of the we're see in capitalizing
We diagnostics continue of to business Biotech company. capital vector completing viral point of European a strategy, rapid a our our Mesa care acquisition execute and molecular deployment
shareholders also buybacks and We through to capital stock our return dividends.
after provider shortly market. end fastest announced to a our research PPD, acquire closed, of the saw, sure As our growing leading pharma quarter serving you I'm customers, biotech services we and clinical agreement
while in financials. of these investing another my each in the cover me of appropriate the our recap quarter in in depth let So for first great remarks stakeholders organically I'll but delivering near-term, and future. topics organically more
grew QX $X.XX XX% in billion. revenue Our to year-over-year
margin and in to income Our XXX% percentage for XX.X%. expanded adjusted $X.XX QX points adjusted XX to operating increased our quarter operating first the billion
share. Finally, to we of adjusted another increase delivered achieving quarter performance, strong per XXX% EPS $X.XX
playing and The activity globally is our response. in economic robust, by sciences, role and three very of end our fundamentals strong markets the factors. to life Turning driven the industry were pandemic ramping conditions
allowed to has position quarter. competitive another Our deliver fantastic unique us
therapeutic our So and XX% customer proposition COVID-XX excellent the with including our customers by growth of strong areas, with vaccines market bio in dynamics, and these and outstanding particularly and across supporting value status mass trusted our our spectrometry that and driven role and performance benefiting spectrometry growth from supporting XX% we've of a bio approximately benefits market customer starting We with across years customers, of businesses clearly pharma driven saw supporting who academic electron production, our base, number earned underlying unique and this chromatography robust our biotech, growth of we businesses services, customer by therapies. channel. performance mass many microscopy. in bio had government, significant partner sciences, leading and range very in globally. with across a these serving safety in activity pharma our saw sciences, customers. wide chromatography strong exciting grew including In research And over all QX and role strong We're
low to high quarter. digits continues the more double team Turning as first their at increase to we opportunities level. to the in activity a execute applied, in The capture and customers industrial very level grew
our was And base while healthcare. see another had outstanding We very growth diagnostics and improving encouraging our across below quarter growth to markets, the business share. returns delivering finally a COVID-XX to testing see market solutions still in end business, teams levels, it in was our strong we strong strong. conditions Demand And pandemic summarize of To the our continue quarter. XXX% and During was capitalized gain good our is our quarter, for approximately all to performance, our instruments pre demand growth. businesses. it immunodiagnostics on
We response testing orders in meaningful vaccine vaccines our and on our in fighting give quarter speed the the production in globally. in our of to represent at development COVID-XX therapies and revenue billion billion continues role $X.X Once and billion Fisher in this very therapies ramp you me we are expected. pandemic in generated we even and and online, role Now, coming Coming vaccines our supporting our to capacity the we let therapy COVID-XX played Demand at strong, supporting QX. Thermo update in to solutions response. and which for revenue again a faster now expect role was $X role year, deliver expected in on in Based expansions than an this XXXX. our $X.X PCR into revenue.
leverage COVID-XX. also with We including schools of businesses to against new the monitoring help to in-air Thermo was our new as to a a identify such Scientific of system solutions in continue hospitals, quarter and facilities presence that causes the expertise example air the the One virus AerosolSenseSampler, pathogens, a fight launch COVID.
spaces, complement to will As public other returned more the AerosolSenseSampler people safety protocols.
very testing by rapid And doctors' including to to Customer cartridges back which decentralized decentralized number rapid Biotech, pharmacies, settings, to we're also high. Mesa. of used and the to -- We business our to diagnostic PPI PCR acquired testing interest Mesa manufacturing scale the simple offices, and using applications. system a adds of life is support
million to capabilities, technology expect and this the this about very molecular excited from pandemic. generate diagnostic year $XXX are We post these potential for
The even future. investments our were make as capability other are the in that pandemic accelerate programs well an is because leading brighter would we R&D, I capacity our accelerated enablement, that XXXX financial Fisher role our of we performance, response and as for to outstanding able These to and really expansions. year significantly positioned like Thermo commercial last point investment for played in
continue me on made into now to turn For build share the investments, innovative to customers. our I'll markets, on these early QX with a success value scale based in innovation. proposition unique for progress emerging a growth customers. is use Watching and delivering that our strategy, examples for from in and growth high strategy we building glimpse value let demonstrate our products, to leveraging create great three high the we how this our few Started on our pillars. impact momentum which new and
our During launched a customers quarter, position to achieve the new and a new and for ground to number their of to goals. products break strengthen leading we across businesses enable
capabilities and Let me which In research our insights Thermo extend atomic Spectra the high analysis microscope scale than of we activity grew metabolomics. to Thermo range improve customer experience has the strengthen particularly electron Spectrometers, we and pillar high We're sciences of and XX%. in in mass for solve the few. we're we an launched to serving to levels, analysis, growth to resolution Apex seeing chromatography and in markets. toxicology including in scale growth, our Exploris pandemic more System a bring Ultra, high two business, continue China, for structural our provides to scanning create Orbitrap GC-Mass a plant throughput our applications, which ScientificOrbitrap to a of sample impact launched outstanding second bio leading customers And our Kingfisher strategy, we our industry highlight further excellent the and transmission returned spectrometry, manufacturing productivity. new Purification Turned where resolution these just to at pre launched leveraging tries for applications, materials science new we generation Scientific emerging growth And preparation. markets. the material In
at facility an and in localize our capacity use the production investment Singapore in started Suzhou, pharma biotech customers single As our use biotech for shipping the in for example, bio single production products in globally. quarter new which in from bio we capabilities customers manufacturing and the China,
strategy, in Turned proposition. strengthen momentum growth our third pillar markets, to strong position. in we and have the we value high growth our our to continue So emerging of customer
for capabilities our to goals. be and our We continue and partner customers increase help them to their better an even achieve capacity
you update customers. me our progress pharma serving and on Let biotech our and
supporting trial combined excellent for of leader with to and the capabilities, in play enhance a Our clinical production. reputation Fisher great research a upcoming world and customers. will complimentary service clinical These proposition biotech a management trials quality Thermo we and development, in complement value PPD is pharma acquisition for further services along
the more customers they're I've our services, partnership, highly capabilities customers Thermo create bring Fisher medicine. these for key to By strategic with able of terrific services idea are and new Importantly, success. number that Scientific. opportunities about interacted portfolio, also work able PPD of our be our and advance our will customers access to improve a complementary announcement, adding scientific which further their since to the our we'll shareholder will bring will provide to career enablers excited will these value. significant colleagues a to our to as It be efficiently
of a building forward. investments globally demand which Our for for and is and other today, many scale a mRNA are up diseases the vaccines, this also also capability going support capacity One high biotech but in customers. of lens COVID-XX pharma for which highlights are organic
sciences in produce our And regions to As materials we're and this different supplier final in drug bio the we're mRNA for we ensuring to important you also continued have due which expanding know, of scalar process. our regionally capacity raw business, production building area. the to essential a an in world. expanded finished including And capacity additional bio available manufacturing sterile is we're resin capacity product. We're capacity purification invest finally,
As and always, drive to even work helped customers, us quarter, all solutions system stakeholders. greater serve and to during our our our ways better PPI success our to create for of efficiently business more effectively, value and the enabling find
summary capital entering Now so had net our quick the for deployment a PPD of active billion mentioned, debt. year. I'll quarter. start, of to $XX.X assumption billion of $X.X as this closing acquisitions We've agreement approximately billion the give plus activities in very just you into in an acquire a far And I $X.X
purchased significant capital dividend to of our by and quarter, XX%. we in the returned like shareholders billion shares increasing also during We $X our
front remains deployment had capital we've pipeline active. great M&A to our the a So and and very start year
very an significantly Turning we to in first And which been make $XX want cleaner in the initiatives, the work. the addition, impact. update businesses. serving our to of and we black world to of safer, million communities support progress to enable relevant. and minority quarter, a proud year, positive over that customers impact mission social never healthier, I'm ESG past in committed financial very to we and more institutions increased And we've a to our our has our impact make communities in live investment brief on the the
meant this more like which just the year, investment for is launched our to all. and for recent project help we create opportunities science, foundation Just last
XXXX. guidance Turning for to our
XX% earnings our Given our guidance revenue will by and $XXX over start million and XXXX. $XX.X I'll billion, revenue year cover by for represents raising year. assumptions We're to we're full the in guidance both behind the the into full year very to the growth guidance Steven highlights. our and get strong our the outlook, confidence raising which our reported
we're adjusted XX% raising In terms $X.XX XXXX. of our to will guidance $XX.XX, growth by EPS, represent over which
create performance We our summarize Before end I call execute of strong. an from to -- proven growth Steven, turn above strategy line. excellent key continue The markets QX. we our financial committed year. to takeaways quarter partner forward to more to XX,XXX value We to to this Thermo for stronger let execute We shareholders. the be about are top the to much delivered looking bottom over me significant even we another our be of our effectively later PPD. at I'm couldn't our capital to Fisher, we for our which welcoming customers. do colleagues deploy acquire customers very is PPD excited plans expect And and
Finally, I'd XX,XXX Thermo to our CFO, And another Williamson. our for company, like dedication quarter. to colleagues thank and call for now their the Stephen fantastic turn our my I'll Steven? Fisher over delivering at once customers, again to